Language: BG BG
nav.cta
Търсене, моля изчакайте...
Филтри 1
Изчисти
Статус
Фаза
Цел
Пол
Възраст
Държава
Филтри 1
Изчисти
Статус
Фаза
Цел
Пол
Възраст
Държава
Активни: Recruiting ×
Намерени 4,436 изпитвания Стр. 162 от 222
Recruiting
Atrial Functional Mitral Regurgitation and Tricuspid Regurgitation
Atrial Fibrillation Functional Mitral Regurgitation Functional Tricuspid Regurgitation

A prospective, observational cohort study designed to identify clinical phenotypes and evaluate predictors \& outcomes of functional mitral and tricuspid valve regurgitation in patients with atrial fibrillation. Participant will under go: * Baseline echocardiography * Cpex Echocardiography * Blood test: BNP * 1 year follow up Echocardiography Participants will be stratified into three subgroups: * Atrial Functional MR * Atrial Functional TR * Mixed MR \& TR

Начало: 23.08.2023 Край: 01.08.2027 Възраст: от 18 г.
United Kingdom Barts & The London NHS Trust NCT05920824
Recruiting Phase 2
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
Atopic Dermatitis

The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic dermatitis (AD). AD is a long- lasting itchy red rash, caused by a skin reaction. This study is seeking participants who: * are 18 years of age or more. * Were confirmed to have AD at least 6 months ago. * Are not having an effective treatment result from medicines that are applied on skin for AD. * Are considered by their doctors to have moderate to severe AD. In Stage 1 of the study, participants will receive either PF-07275315 or PF-07264660 or placebo. Stage 1 is complete. In Stage 2 of the study participants will receive either PF-07275315 or placebo. In Stage 3 of the study participants who have received anti-inflammatory proteins, will receive either PF-07275315 or placebo. In Stage 4 of the study participants will receive either PF-07264660 or placebo. A placebo does not have any medicine in it but looks just like the medicines being studied. PF-07275315 or PF-07264660 or placebo will be given as multiple shots in the clinic over the course of each Stage. The experiences of people receiving PF-07275315 or PF-07264660 will be compared to people who do not. This will help determine if PF-07275315 and PF-07264660 are safe and effective. Participants in Stages 1, 2 and 4 will be involved in this study for up to 40 weeks (10 months). Participants in Stage 3 will be involved in this study for up to 52 weeks (13 months).

Начало: 22.08.2023 Край: 08.03.2027 Възраст: от 18 г. Treatment
Australia, Canada, China +4 Pfizer NCT05995964
Recruiting Phase 4
The Peri-OPerative COlchicine to Reduce Negative Events (POPCORN) Trial
Coronary Artery Disease

Heart disease remains the leading cause of death in Veterans. Inflammation in the arteries of the heart may increase the risk of cardiac death. Patients with heart disease undergoing major surgery are at increased risk of complications after surgery, including heart attack, stroke, and death. The proposed research seeks to better understand the role of inflammation in the damage to the heart and blood vessels after major surgery. This research also seeks to identify the potential beneficial role of a safe medication, colchicine, which has direct effects on inflammatory cells and has been used in the treatment of inflammatory diseases for more than 2000 years, on reducing the rate of complications after surgery. With its quick onset of action and excellent safety profile, colchicine may have the potential to reduce risk of heart injury, stroke, or death after major surgery.

Начало: 21.08.2023 Край: 30.04.2029 Възраст: от 18 г.
United States VA Office of Research and Development NCT05618353
Recruiting
OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
ATTR Amyloidosis

The overall aim of this observational study is to generate real-world evidence on the pre- and post-diagnosis disease journeys, including baseline characteristics, treatment patterns and selected clinical, economic, and humanistic outcomes (for example Health Related Quality of Life (HRQoL), Neuropathy impairment score, activities of daily living (ADL) assessments) in patients with ATTR amyloidosis, and to better understand how the disease is presented.

Начало: 21.08.2023 Край: 30.09.2026
Canada, China, Denmark +7 AstraZeneca NCT06355934
Recruiting
5-Cog 2.0: A Pragmatic Clinical Trial
Dementia Cognitive Impairment

Cognitive impairment related to dementia is frequently under-diagnosed in primary care settings. This problem is more prevalent in health disparities populations. The investigators developed the 5-Cog brief cognitive assessment that is simple to use, standardized, takes \

Начало: 18.08.2023 Край: 01.11.2027 Възраст: от 65 г.
United States Albert Einstein College of Medicine NCT05515224
Recruiting Phase 1/2
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
Advanced Solid Tumor Metastatic Solid Tumor

This study will evaluate the safety, tolerability, and efficacy of DS-3939a in participants with advanced solid tumors.

Начало: 18.08.2023 Край: 15.02.2027 Възраст: от 18 г.
Belgium, Canada, China +5 Daiichi Sankyo NCT05875168
Recruiting Phase 3
A Trial to Treat Polyomavirus Infections (BKPyV) in Kidney and Simultaneous Kidney Pancreas Transplant Recipients
BK Viremia Kidney Transplant Infection Kidney Transplant Failure and Rejection

BEAT-BK will see the effect of immunosuppression reduction/modification with and without IVIG on BKPyV infection, allograft function, allograft loss, acute transplant rejection, immunosuppression load and death in kidney and simultaneous kidney pancreas transplant recipients with polyomavirus infections (BKPyV).

Начало: 18.08.2023 Край: 30.06.2029 Възраст: от 2 г. Treatment
Australia The University of Queensland NCT05325008
Recruiting Phase 1/2
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Advanced Solid Tumors

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.

Начало: 17.08.2023 Край: 01.05.2028 Възраст: от 18 г. Treatment
Australia, China, Taiwan +1 DualityBio Inc. NCT05914116
Recruiting Phase 2
The Effect of Intra-sinus Application of Betamethasone Dipropionate Nasal Cream on Patients with Chronic Rhinosinusitis Post Functional Endoscopic Sinus Surgery (FESS)
Chronic Rhinosinusitis (Diagnosis)

To assess the safety and efficacy of one (single) application of Betamethasone Dipropionate Nasal Cream (BMDP CREAM) onto the sinus mucosa.

Начало: 17.08.2023 Край: 01.06.2025 Възраст: 18–80 г. Treatment
Australia Oticara Australia PTY LTD NCT05882903
Recruiting
Sedation, Temperature and Pressure After Cardiac Arrest and Resuscitation
Cardiac Arrest With Successful Resuscitation Hypoxia, Brain

The STEPCARE-trial is a 2x2x2 randomised trial studying patients who have been resuscitated from cardiac arrest and who are comatose. It will include three different interventions focusing on sedation targets, temperature targets and mean arterial pressure targets.

Начало: 17.08.2023 Край: 01.12.2026 Възраст: от 18 г. Treatment
Australia, Belgium, Estonia +11 Region Skane NCT05564754
Recruiting Phase 2
Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients
Radiation Induced Fibrosis

This study will evaluate the efficacy of losartan (LOS), an FDA-approved transforming growth factor beta-1 (TGF-β1) blocker, to decrease radiation induced fibrosis (RIF) in the breast and the lung of breast cancer patients, testing the hypothesis that Losartan will decrease RIF, TGF- β1 and cellular senescence/inflammation in the breast and the lung of irradiated breast cancer patients relative to placebo treatment and consequently improve clinical outcomes in breast cancer patients.

Начало: 17.08.2023 Край: 17.08.2027 Възраст: от 18 г.
United States Shaw Cancer Center NCT05637216
Recruiting Phase 4
Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits
Epilepsy

Methylphenidate (MPH) is a stimulant, FDA-approved for the treatment of attention deficit hyperactivity disorder (ADHD). It is unknown, however, if stimulants would be of benefit for memory and thinking problems due to epilepsy. In this study, participants will be assigned randomly (i.e., by flip of a coin), to a group that takes MPH and a group that takes a placebo (sugar pill). Participants will not know the group to which they have been assigned. Tests of attention and memory will be completed before taking the study pills and at Week 8. All participants will then have the option of taking MPH for the next two months, and attention and memory will be tested again at Week 16. The study will determine whether methylphenidate is helpful for the treatment of attention and memory problems in adults with epilepsy, and whether the medication is safe and beneficial when taken over an extended time period.

Начало: 14.08.2023 Край: 31.05.2028 Възраст: от 18 г.
United States VA Office of Research and Development NCT04419272
Recruiting
A Personalised Approach Utilising the Frailty Index to Empower Consumers
Gastrointestinal Diseases

Frailty is a common clinical syndrome in older adults that may carry an increased risk for poor health outcomes including falls, hospitalisation, and mortality. Having a colonoscopy can be associated with potential adverse outcomes in frail patients. At present, however, frailty is not routinely assessed in gastroenterological clinical practice. In a prospective randomised controlled study consenting patients over 65 years at the Princess Alexandra Hospital will receive either a) personalised (tailored) approach that includes assessment of frailty and structured information provided to the consumer or b) current standard practice in regards to having a surveillance colonoscopy to determine the effects on patient satisfaction and percentage of colonoscopies avoided.

Начало: 14.08.2023 Край: 01.02.2026 Възраст: 65–100 г. Screening
Australia Princess Alexandra Hospital, Brisbane, Australia NCT05292989
Recruiting Phase 1
Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
Hormone-refractory Prostate Cancer

The study will be conducted in 4 parts and will commence with dose escalation of VIR-5500 as a monotherapy (Part 1), followed by combination escalation (Part 3a), monotherapy dose expansion (Part 2) and combination dose expansion (Part 4a). * Part 1 (Monotherapy Dose Escalation): Single-agent VIR-5500 dose escalation * Part 2 (Monotherapy Dose Expansion): Single-agent VIR-5500 dose expansion * Part 3 (Combination Dose Escalation): VIR-5500 plus another therapeutic agent dose escalation o Part 3a (Combination Dose Escalation): VIR-5500 in combination with an androgen receptor signaling inhibitor (ARSI) (enzalutamide or darolutamide) * Part 4 (Combination Dose Expansion): VIR-5500 plus another therapeutic agent dose expansion o Part 4a (Combination Dose Expansion): VIR-5500 in combination with an ARSI (enzalutamide or darolutamide)

Начало: 10.08.2023 Край: 29.09.2027 Възраст: от 18 г. Treatment
Australia, Spain, United Kingdom +1 Vir Biotechnology, Inc. NCT05997615
Recruiting Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Relapsed or Refractory Multiple Myeloma

The purpose of the study is to evaluate safety and tolerability of the combination of cevostamab plus elranatamab and also determine the recommended Phase II regimen (RP2R) for the study treatment. The study consists of a safety lead-in stage, and an expansion stage.

Начало: 10.08.2023 Край: 31.07.2027 Възраст: от 18 г. Treatment
Australia, Israel, South Korea Genentech, Inc. NCT05927571
Recruiting Phase 2
Reboxetine for Sleep Apnoea After ENT Surgery
Sleep Apnea, Obstructive

This pilot study will establish the feasibility of a larger trial to investigate whether reboxetine, a medication used to treat depression, can reduce the severity of obstructive sleep apnea (OSA) including increased blood oxygenation in post-surgical OSA patients where positive airway pressure (CPAP) therapy is either frequently poorly tolerated or not an option immediately post surgery. In this randomized, placebo-controlled, double-blind study, participants will use at-home sleep monitoring equipment before and after surgery plus measures of oxygenation. They will be prescribed either reboxetine or a placebo for seven days after surgery and complete questionnaires at the beginning and end of the study.

Начало: 10.08.2023 Край: 01.07.2025 Възраст: от 18 г. Other
Australia Flinders University NCT05978505
Recruiting
Avatar-mediated Therapy Versus Cognitive Behavioural Therapy for Persisting Experiences of Hearing Voices
Auditory Hallucination Psychotic Disorders Schizophrenia and Related Disorders

The aim of this study is to compare the effects of a new psychological therapy, Avatar Therapy, to the current standard therapy, Cognitive Behavioural Therapy (CBT), in improving outcomes in people living with psychotic disorders who have persisting experiences of hearing voices (auditory verbal hallucinations, AVHs).

Начало: 08.08.2023 Край: 01.06.2027 Възраст: от 18 г. Treatment
Australia Swinburne University of Technology NCT05982158
Recruiting Phase 3
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
Primary IgA Nephropathy

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of sefaxersen (RO7434656), a novel Antisense Oligonucleotide (ASO) therapy in participants with primary IgA nephropathy (IgAN) who are at high risk of progressive kidney disease despite optimized supportive care.

Начало: 08.08.2023 Край: 31.03.2029 Възраст: от 18 г. Treatment
Argentina, Australia, Brazil +18 Hoffmann-La Roche NCT05797610
Recruiting Phase 3
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Leukemia, Lymphocytic, Chronic, B-Cell Leukemia, Chronic Lymphocytic Small-Cell Lymphoma Lymphoma, Small Lymphocytic +2

The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrutinib plus venetoclax is superior to VR with respect to progression-free survival (PFS) per 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria as assessed by blinded independent central review (BICR).

Начало: 08.08.2023 Край: 01.07.2035 Възраст: от 18 г. Treatment
Argentina, Australia, Belgium +15 Merck Sharp & Dohme LLC NCT05947851
Recruiting Phase 1/2
Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients
Paroxysmal Nocturnal Hemoglobinuria (PNH)

The first-in-human Phase 1/Phase 2a study described herein will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in both healthy participants (HP) and in patients with paroxysmal nocturnal hemoglobinuria (PNH).

Начало: 07.08.2023 Край: 31.07.2028 Възраст: от 18 г. Treatment
Australia, United Kingdom ADARx Pharmaceuticals, Inc. NCT05876312
1 … 160 161 162 163 164 … 222